ing. D.F. Samplonius

Faculty of Medical Sciences

Telephone:

+31 50 361 8018

E-mail:

d.f.samplonius umcg.nl

ORCID Research Portal

Publications

CD19-ReTARGtpr: A Novel Fusion Protein for Physiological Engagement of Anti-CMV Cytotoxic T Cells Against CD19-Expressing Malignancies.

van Wijngaarden, A. P., Britsch, I., Peipp, M., Samplonius, D. F. & Helfrich, W., 10-Jul-2025, In: Cancers. 17, 14, 17 p.

Research output: Contribution to journal › Article › Academic › peer-review

Enhancing the Anticancer Activity of a Carcinoma-Directed Peptide-HLA-I Fusion Protein by Armoring with Mutein IFNα

Samplonius, D. F., van Wijngaarden, A. P., Koll, L., Ke, X. & Helfrich, W., 29-Mar-2025, In: International Journal of Molecular Sciences. 26, 7, 19 p., 3178.

Research output: Contribution to journal › Article › Academic › peer-review

Synthesis and in vitro comparison of [18F]bicalutamide and [123I]bicalutamide, two novel androgen receptor radioligands for PET/SPECT imaging

Diekstra, E., Kurniawan, A. A., Mayenco, N. D., Samplonius, D., Helfrich, W., Cornelissen, B., de Vries, E. & Antunes, I., Nov-2025, In: Nuclear Medicine and Biology. 150-151, 2 p., 109435.

Research output: Contribution to journal › Meeting Abstract › Academic

Synthesis and in vitro evaluation of [18F]Bicalutamide, a novel androgen receptor radioligand

Diekstra, E., Hernandez Cano, L., Delgado Mayenco, N., Samplonius, D., Helfrich, W., Cornelissen, B., de Vries, E. F. & F. Antunes, I., 2024, p. 16. 1 p.

Research output: Contribution to conference › Poster › Academic

Visible Light Control over the Cytolytic Activity of a Toxic Pore-Forming Protein

Volarić, J., van der Heide, N. J., Mutter, N. L., Samplonius, D. F., Helfrich, W., Maglia, G., Szymanski, W. & Feringa, B. L., 16-Feb-2024, In: ACS chemical biology. 19, 2, p. 451–461 11 p., 3c00640.

Research output: Contribution to journal › Article › Academic › peer-review

A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer

Ploeg, E. M., Britsch, I., van Wijngaarden, A. P., Ke, X., Hendriks, M. A. J. M., Samplonius, D. F. & Helfrich, W., Jul-2023, In: Cancers. 15, 14, 15 p., 3651.

Research output: Contribution to journal › Article › Academic › peer-review

Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR

Ploeg, E. M., Samplonius, D. F., Xiong, X., Ke, X., Hendriks, M. A. J. M., Britsch, I., Van Wijngaarden, A. P., Zhang, H. & Helfrich, W., 21-Sept-2023, In: Journal for immunotherapy of cancer. 11, 9, 15 p., e006837.

Research output: Contribution to journal › Article › Academic › peer-review

Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells

Britsch, I., van Wijngaarden, A. P., Ke, X., Hendriks, M. A. J. M., Samplonius, D. F., Ploeg, E. M. & Helfrich, W., 2023, In: OncoImmunology. 12, 1, 2207868.

Research output: Contribution to journal › Article › Academic › peer-review

A proof-of-concept study on the use of a fluorescein-based 18F-tracer for pretargeted PET

Helbert, H., Ploeg, E. M., Samplonius, D. F., Blok, S. N., Antunes, I. F., Böhmer, V. I., Luurtsema, G., Dierckx, R. A. J. O., Feringa, B. L., Elsinga, P. H., Szymanski, W. & Helfrich, W., 3-Mar-2022, In: EJNMMI Radiopharmacy and Chemistry. 7, 1, 11 p., 3.

Research output: Contribution to journal › Article › Academic › peer-review

Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles

Ploeg, E. M., Ke, X., Britsch, I., Hendriks, M. A. J. M., Van der Zant, F. A., Kruijff, S., Samplonius, D. F., Zhang, H. & Helfrich, W., 28-Nov-2021, In: Cancer letters. 521, p. 109-118 10 p.

Research output: Contribution to journal › Article › Academic › peer-review

All (44) publications

View full research profile

ing. D.F. Samplonius

Publications

Functional

Standard

Complete